384 related articles for article (PubMed ID: 30379592)
1. ACVR1
Haupt J; Stanley A; McLeod CM; Cosgrove BD; Culbert AL; Wang L; Mourkioti F; Mauck RL; Shore EM
Mol Biol Cell; 2019 Jan; 30(1):17-29. PubMed ID: 30379592
[TBL] [Abstract][Full Text] [Related]
2. The ACVR1 R206H mutation found in fibrodysplasia ossificans progressiva increases human induced pluripotent stem cell-derived endothelial cell formation and collagen production through BMP-mediated SMAD1/5/8 signaling.
Barruet E; Morales BM; Lwin W; White MP; Theodoris CV; Kim H; Urrutia A; Wong SA; Srivastava D; Hsiao EC
Stem Cell Res Ther; 2016 Aug; 7(1):115. PubMed ID: 27530160
[TBL] [Abstract][Full Text] [Related]
3. Elevated BMP and Mechanical Signaling Through YAP1/RhoA Poises FOP Mesenchymal Progenitors for Osteogenesis.
Stanley A; Heo SJ; Mauck RL; Mourkioti F; Shore EM
J Bone Miner Res; 2019 Oct; 34(10):1894-1909. PubMed ID: 31107558
[TBL] [Abstract][Full Text] [Related]
4. Depletion of Mast Cells and Macrophages Impairs Heterotopic Ossification in an Acvr1
Convente MR; Chakkalakal SA; Yang E; Caron RJ; Zhang D; Kambayashi T; Kaplan FS; Shore EM
J Bone Miner Res; 2018 Feb; 33(2):269-282. PubMed ID: 28986986
[TBL] [Abstract][Full Text] [Related]
5. Molecular consequences of the ACVR1(R206H) mutation of fibrodysplasia ossificans progressiva.
Song GA; Kim HJ; Woo KM; Baek JH; Kim GS; Choi JY; Ryoo HM
J Biol Chem; 2010 Jul; 285(29):22542-53. PubMed ID: 20463014
[TBL] [Abstract][Full Text] [Related]
6. Palovarotene Inhibits Heterotopic Ossification and Maintains Limb Mobility and Growth in Mice With the Human ACVR1(R206H) Fibrodysplasia Ossificans Progressiva (FOP) Mutation.
Chakkalakal SA; Uchibe K; Convente MR; Zhang D; Economides AN; Kaplan FS; Pacifici M; Iwamoto M; Shore EM
J Bone Miner Res; 2016 Sep; 31(9):1666-75. PubMed ID: 26896819
[TBL] [Abstract][Full Text] [Related]
7. Overexpression of Wild-Type ACVR1 in Fibrodysplasia Ossificans Progressiva Mice Rescues Perinatal Lethality and Inhibits Heterotopic Ossification.
Yamamoto M; Stoessel SJ; Yamamoto S; Goldhamer DJ
J Bone Miner Res; 2022 Nov; 37(11):2077-2093. PubMed ID: 35637634
[TBL] [Abstract][Full Text] [Related]
8. Functional Testing of Bone Morphogenetic Protein (BMP) Pathway Variants Identified on Whole-Exome Sequencing in a Patient with Delayed-Onset Fibrodysplasia Ossificans Progressiva (FOP) Using ACVR1
Wentworth KL; Lalonde RL; Groppe JC; Brewer N; Moody T; Hansberry S; Taylor KE; Shore EM; Kaplan FS; Pignolo RJ; Yelick PC; Hsiao EC
J Bone Miner Res; 2022 Nov; 37(11):2058-2076. PubMed ID: 36153796
[TBL] [Abstract][Full Text] [Related]
9. An Acvr1 R206H knock-in mouse has fibrodysplasia ossificans progressiva.
Chakkalakal SA; Zhang D; Culbert AL; Convente MR; Caron RJ; Wright AC; Maidment AD; Kaplan FS; Shore EM
J Bone Miner Res; 2012 Aug; 27(8):1746-56. PubMed ID: 22508565
[TBL] [Abstract][Full Text] [Related]
10. Role of altered signal transduction in heterotopic ossification and fibrodysplasia ossificans progressiva.
Shore EM; Kaplan FS
Curr Osteoporos Rep; 2011 Jun; 9(2):83-8. PubMed ID: 21340697
[TBL] [Abstract][Full Text] [Related]
11. ACVR1R206H receptor mutation causes fibrodysplasia ossificans progressiva by imparting responsiveness to activin A.
Hatsell SJ; Idone V; Wolken DM; Huang L; Kim HJ; Wang L; Wen X; Nannuru KC; Jimenez J; Xie L; Das N; Makhoul G; Chernomorsky R; D'Ambrosio D; Corpina RA; Schoenherr CJ; Feeley K; Yu PB; Yancopoulos GD; Murphy AJ; Economides AN
Sci Transl Med; 2015 Sep; 7(303):303ra137. PubMed ID: 26333933
[TBL] [Abstract][Full Text] [Related]
12. Activin A amplifies dysregulated BMP signaling and induces chondro-osseous differentiation of primary connective tissue progenitor cells in patients with fibrodysplasia ossificans progressiva (FOP).
Wang H; Shore EM; Pignolo RJ; Kaplan FS
Bone; 2018 Apr; 109():218-224. PubMed ID: 29170109
[TBL] [Abstract][Full Text] [Related]
13. Reduced GS Domain Serine/Threonine Requirements of Fibrodysplasia Ossificans Progressiva Mutant Type I BMP Receptor ACVR1 in the Zebrafish.
Allen RS; Jones WD; Hale M; Warder BN; Shore EM; Mullins MC
J Bone Miner Res; 2023 Sep; 38(9):1364-1385. PubMed ID: 37329499
[TBL] [Abstract][Full Text] [Related]
14. Allele-Selective LNA Gapmers for the Treatment of Fibrodysplasia Ossificans Progressiva Knock Down the Pathogenic ACVR1
Maruyama R; Nguyen Q; Roshmi RR; Touznik A; Yokota T
Nucleic Acid Ther; 2022 Jun; 32(3):185-193. PubMed ID: 35085461
[TBL] [Abstract][Full Text] [Related]
15. The obligatory role of Activin A in the formation of heterotopic bone in Fibrodysplasia Ossificans Progressiva.
Alessi Wolken DM; Idone V; Hatsell SJ; Yu PB; Economides AN
Bone; 2018 Apr; 109():210-217. PubMed ID: 28629737
[TBL] [Abstract][Full Text] [Related]
16. Fibrodysplasia ossificans progressiva: a human genetic disorder of extraskeletal bone formation, or--how does one tissue become another?
Shore EM
Wiley Interdiscip Rev Dev Biol; 2012; 1(1):153-65. PubMed ID: 22408652
[TBL] [Abstract][Full Text] [Related]
17. BMP signaling and skeletal development in fibrodysplasia ossificans progressiva (FOP).
Towler OW; Shore EM
Dev Dyn; 2022 Jan; 251(1):164-177. PubMed ID: 34133058
[TBL] [Abstract][Full Text] [Related]
18. The Fibrodysplasia Ossificans Progressiva (FOP) mutation p.R206H in ACVR1 confers an altered ligand response.
Hildebrand L; Stange K; Deichsel A; Gossen M; Seemann P
Cell Signal; 2017 Jan; 29():23-30. PubMed ID: 27713089
[TBL] [Abstract][Full Text] [Related]
19. Alk2 regulates early chondrogenic fate in fibrodysplasia ossificans progressiva heterotopic endochondral ossification.
Culbert AL; Chakkalakal SA; Theosmy EG; Brennan TA; Kaplan FS; Shore EM
Stem Cells; 2014 May; 32(5):1289-300. PubMed ID: 24449086
[TBL] [Abstract][Full Text] [Related]
20. Modeling the
Barruet E; Garcia SM; Wu J; Morales BM; Tamaki S; Moody T; Pomerantz JH; Hsiao EC
Elife; 2021 Nov; 10():. PubMed ID: 34755602
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]